Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.66 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.51 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | PPARD | Q03181 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5064518 | 0.85 | CCR1 (0.89) | CCR1PTGDR2 | |
| SCHEMBL6077572 | 0.81 | CCR1 (0.58) | CCR1PTGDR2 | |
| SCHEMBL6075883 | 0.80 | CCR1 (1.00) | CCR1PTGDR2 | |
| SCHEMBL5060051 | 0.78 | CCR1 (0.87) | CCR1PTGDR2 | |
| SCHEMBL6077064 | 0.77 | CCR1 (0.62) | CCR1PTGDR2KDM4EMEN1ALDH1A1 | |
| SCHEMBL6077219 | 0.75 | CCR1 (0.56) | CCR1PTGDR2KDM4EMEN1ALDH1A1 | |
| SCHEMBL5055443 | 0.74 | PTGDR2 (0.78) | CCR1PTGDR2 | |
| SCHEMBL6076376 | 0.72 | CCR1 (0.77) | CCR1PTGDR2 | |
| SCHEMBL6077443 | 0.72 | CCR1 (0.86) | CCR1PTGDR2 | |
| SCHEMBL6076172 | 0.72 | CCR1 (0.86) | CCR1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098212-B2 | Piperazine derivatives | BLUMBERG LAURA C | 2006-08-29 | — | — | US | disclosed |
| US-20040034034-A1 | Novel piperazine derivatives | BLUMBERG LAURA C (US) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034034-A1 | Novel piperazine derivatives | CCR1, CCRL2, CCR5 | CCR1 1/4885PTGDR2 190/4885PPARG 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.